Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtide.
The aim of this pilot study was to assess whether enfuvirtide can be discontinued in patients on long-term viral suppression. Eight patients with multidrug-resistant virus were randomly assigned to stop and 10 subjects to continue enfuvirtide. At week 48, viral rebound occurred in five (62.5%) and in no patients, respectively, (P = 0.007). The CD4 cell decrease in failure patients was 5% (P = ns). These results suggest that enfuvirtide should be maintained until new active drugs became available.
Bonjoch
Anna
A
Lluita Contra la SIDA Foundation, AIDS Care Unit, Hospital Universitari Germans Trias i Pujol, Universitat Auntònoma de Barcelona, Badalona, Spain.
Negredo
Eugenia
E
Puig
Jordi
J
Erkizia
Itziar
I
Puig
Teresa
T
Cabrera
Cecilia
C
Ruiz
Lidia
L
Clotet
Bonaventura
B
D051997:ADP-ribosyl Cyclase 1 / Q000032:analysis; D018791:CD4 Lymphocyte Count; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D024882:Drug Resistance, Viral / Q000276:immunology; D000077560:Enfuvirtide; D006678:HIV / Q000276:immunology; D015700:HIV Envelope Protein gp41 / Q000276:immunology / Q000627:therapeutic use*; D023581:HIV Fusion Inhibitors / Q000276:immunology / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D006801:Humans; D009154:Mutation; D010446:Peptide Fragments / Q000276:immunology / Q000627:therapeutic use*; D010865:Pilot Projects; D011446:Prospective Studies
D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D000077560:Enfuvirtide; D051997:ADP-ribosyl Cyclase 1